Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: Findings and implications

Journal of Comparative Effectiveness Research

Volumn 3, Issue 1, 2014, Pages 41-51

  Martin, Andrew ^a   Godman, Brian ^b,c,d   Miranda, Jamilette ^e   Tilstone, Jeanette ^f   Saleem, Nigget ^f   Olsson, Erika ^g   Acosta, Angela ^h   Restrepo, Luis ⁱ   Bennie, Marion ^b  

^a NHS Greater Manchester Commissioning Support Unit   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e STOCKHOLM COUNTY COUNCIL   (Sweden)

^f NHS Bury Clinical Commissioning Group   (United Kingdom)

^g UPPSALA UNIVERSITY   (Sweden)

^h UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

ⁱ National College of Pharmacist Chemists of Colombia   (Colombia)

Author keywords

demand side measures; drug utilization study; generics; losartan; UK

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; GENERIC DRUG; LOSARTAN;

ARTICLE; COST CONTROL; DRUG COST; DRUG UTILIZATION; HUMAN; HYPERTENSION; PHARMACIST; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; UNITED KINGDOM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; COST SAVINGS; COSTS AND COST ANALYSIS; DRUG UTILIZATION; DRUGS, GENERIC; GREAT BRITAIN; HUMANS; HYPERTENSION; INSERVICE TRAINING; LOSARTAN; PHYSICIAN'S PRACTICE PATTERNS; STATE MEDICINE;

EID: 84890915187     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.13.83     Document Type: Article

References (45)

1. Godman B, Bennie M, Baumgärtel C et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia Health Econ. Ther. Pathways 13(Suppl. 3), 5-20 (2012).
2. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24 (2010).
3. Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722 (2010).
4. Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1, 141 (2011).
5. Vonina L, Strizrep T, Godman B et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469-479 (2011).
6. Godman B, Wettermark B, Hoffman M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65-83 (2009).
7. Godman B, Abuelkhair M, Vitry A et al. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. GABI J. 1(2), 69-83 (2012).
8. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems -a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138 (2008).
9. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 73-85 (2010).
10. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the PPIs and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12, 125-130 (2012).
11. Godman B, Malmstrom RE, Bennie M et al. Prescribing restrictions -a necessary strategy among some European countries to enhance future prescribing efficiency? Rev. Health Care 3, 5-16 (2012).
12. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11, 121-129 (2011).
13. van Woerkom M, Piepenbrink JF, Godman B et al. Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in The Netherlands: influence and future implications. J. Comp. Effect. Res. 1, 527-538 (2012).
14. Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 13(4), 469-482 (2013).
15. Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94, 221-229 (2010).
16. Frisk P, Mellgren TO, Hedberg N et al. Utilisation of angiotensin blockers in Sweden combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol. 64, 1223-1229 (2008).
17. Fletcher A, Palmer A, Bulpitt C. Coughing with angiotensin converting enzyme inhibitors: how much of a problem? J. Hypertens. Suppl. 12(2), S43-S47 (1994).
18. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480-484 (2008).
19. Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug budget. BMJ 342, 30-32 (2011).
20. Gustafsson LL, Wettermark B, Godman B et al. The 'Wise List' -a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108, 224-233 (2011).
21. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking -an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 137-147 (2009).
22. Bennie M, Bishop I, Godman B et al. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? Qual. Prim. Care 21, 7-15 (2013).
23. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 27, 299-309 (2002).
24. McDowall D, McCleary R, Meidinger EE, Hay RA. Interrupted time series analysis. In: Sage University Papers Series on Quantitative Applications in the Social Sciences. Sage Publications, Inc., CA, USA (1980).
25. Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH. Examining product risk in context. Market withdrawal of Zomepirac as a case study. JAMA 270, 1937-1942 (1993).
26. Durbin J, Watson GS. Testing for serial correlation in least square regression. Biometrika 37, 409-428 (1951).
27. Brennan P, Croft P. Interpreting the results of observational research: chance is not such a fine thing. BMJ 309, 727-730 (1994).
28. Szecseny J. Influence of attitudes and behaviour of GPs on prescribing costs. Qual. Saf. Health Care 12, 6-7 (2003).
29. Godman B, Bennett K, Bennie M et al. Variable approaches to enhancing the prescribing of losartan once generics available: influence and future direction. Pharmacoepidemiol. Drug Saf. 21(Suppl. 3), 295 (2012).
30. Olsson E, Sporrong SK. Pharmacists experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int. J. Pharm. Pract. 6, 377-383 (2012).
31. Olsson E, Ingman P, Ahmed A, Kälvemark Sporrong S. Pharmacist-patient communication in Swedish community pharmacists. Res. Social Adm. Pharm. doi:10.1016/j.sapharm.2013.03.001 (2013) (Epub ahead of print).
32. Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N. Engl. J. Med. 355, 375-384 (2006).
33. Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmström RE. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Int. J. Clin. Pract. 67(9), 853-862 (2013).
34. Hesse U, Godman B, Petzold M, Martin A, Malmström RE. Impact of delisting ARBs apart from losartan on ARB utilisation patterns in Denmark: implications for other countries. Appl. Health Econ. Health Policy doi:10.1007/s40258-013-0059-4 (2013) (Epub ahead of print).
35. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst. Rev. (4), CD003822 (2008).
36. Svanström H, Pasternak B, Hviid A. Association of treatment with losartan vs. candesartan and mortality among patients with heart failure. JAMA 307, 1506-1512 (2012).
37. OECD. Health at a Glance 2011: OECD Indicators (2011). www.oecd.org/els/health-systems/49105858. pdf (Accessed 10 September 2013)
38. NHS. Better care, better value indicators. www.institute.nhs.uk/quality- and-value/ high-volume-care/better-care-better-value- indicators.html (Accessed 5 September 2013)
39. Office of Fair Trading (UK). The pharmaceutical price regulation system: an OFT study. Annexe A: market for prescription pharmaceuticals in the NHS (2007). www.oft.gov.uk/shared-oft/reports/comp- policy/oft885a.pdf (Accessed 6 September 2013)
40. MeReC. Key therapeutic targets; medicines management options for local implementation (2011). www.npc.nhs.uk/qipp/resources/qipp-key- therapeutic-topics-july11-version3.1.v2.pdf (Accessed 3 September 2013)
41. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. www.whocc.no/atc-ddd-index (Accessed 5 September 2013)
42. NHS pay. Agenda for change -pay rates from April 2012. www.nhscareers.nhs.uk/details/default. aspx?id=766 (Accessed 3 September 2013)
43. NHS Employers. Pay circular (AfC) 2/2012. www.nhsemployers.org/Aboutus/ Publications/PayCirculars/Pages/ PayCircularAforC22012.aspx (Accessed 3 September 2013)
44. National Audit Office. NHS pay modernisation in England: agenda for change. www.nao.org.uk/publications/0809/nhs- pay-modernisation.aspx (Accessed 3 September 2013)
45. MeReC. NICE updates its guidance on the management of hypertension (2011). www.npc.nhs.uk/rapidreview/?p=4470 (Accessed 3 September 2013)